Vivos Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Vivos Therapeutics

09/05/2025 17:18

Vivos Therapeutics Inc VVOS.OQ VVOS.O is expected to show a rise in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

The Littleton Colorado-based  company is expected to report a 7.2% increase in revenue to $3.667 million from $3.42 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Vivos Therapeutics Inc is for a loss of 40 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Vivos Therapeutics Inc is $5.85​, above​ its last closing price of $2.84. ​​​

This summary was machine generated May 9 at 16:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)